Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer.
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S; Japanese Breast Cancer Society. Mukai H, et al. Among authors: akabane h. Breast Cancer. 2015 Jan;22(1):5-15. doi: 10.1007/s12282-014-0563-x. Epub 2014 Sep 9. Breast Cancer. 2015. PMID: 25200171 No abstract available.
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Shiroiwa T, et al. Among authors: akabane h. Qual Life Res. 2017 Feb;26(2):445-453. doi: 10.1007/s11136-016-1388-1. Epub 2016 Aug 12. Qual Life Res. 2017. PMID: 27517267 Free PMC article. Clinical Trial.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y. Iwata H, et al. Among authors: akabane h. Breast Cancer Res Treat. 2019 Jan;173(1):123-133. doi: 10.1007/s10549-018-4964-y. Epub 2018 Sep 21. Breast Cancer Res Treat. 2019. PMID: 30242578 Free PMC article. Clinical Trial.
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y. Mukai H, et al. Among authors: akabane h. Br J Cancer. 2020 Jun;122(12):1747-1753. doi: 10.1038/s41416-020-0815-9. Epub 2020 Apr 2. Br J Cancer. 2020. PMID: 32238920 Free PMC article. Clinical Trial.
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T, Hozumi Y, Sagara Y, Takahashi M, Yoneyama K, Fujisawa T, Osumi S, Akabane H, Nishimura R, Mieno MN, Mukai H. Yamaguchi T, et al. Among authors: akabane h. Surg Oncol. 2021 Mar;36:51-55. doi: 10.1016/j.suronc.2020.11.008. Epub 2020 Nov 20. Surg Oncol. 2021. PMID: 33310293 Clinical Trial.
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. Takashima T, et al. Among authors: akabane h. Clin Breast Cancer. 2021 Oct;21(5):450-457. doi: 10.1016/j.clbc.2021.01.018. Epub 2021 Feb 1. Clin Breast Cancer. 2021. PMID: 33685834
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.
Iwata H, Yamamoto Y, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Ohtani S, Kashiwaba M, Taira N, Toyama T, Fujisawa T, Masuda N, Shibahara Y, Sasano H, Yamaguchi T. Iwata H, et al. Among authors: akabane h. Breast Cancer Res Treat. 2023 Jun;199(2):231-241. doi: 10.1007/s10549-023-06874-7. Epub 2023 Mar 22. Breast Cancer Res Treat. 2023. PMID: 36947277 Free PMC article. Clinical Trial.
78 results